Encompass Health (EHC) has been beaten down lately with too much selling pressure. While the stock has lost 10.4% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of ...

Core Viewpoint - Amphastar Pharmaceuticals (AMPH) has experienced a significant downtrend, with a 13.1% decline in stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to improved earnings expectations from analysts [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2]. - AMPH's current RSI reading is 29.97, suggesting that the heavy selling pressure may be exhausting, indicating a possible bounce back towards equilibrium in supply and demand [5]. Group 2: Fundamental Analysis - Analysts have shown strong consensus in raising earnings estimates for AMPH, with a 3.4% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [7]. - AMPH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8].

Group 1 - North American Construction (NOA) has experienced significant selling pressure, with a decline of 8.6% over the past four weeks, but is now positioned for a potential trend reversal as it is in oversold territory [1] - The Relative Strength Index (RSI) for NOA is currently at 29.98, indicating that the stock is oversold and may soon experience a reversal towards its previous equilibrium of supply and demand [5] - There is a strong consensus among Wall Street analysts that NOA will report better earnings than previously predicted, with a 0.6% increase in the consensus EPS estimate over the last 30 days [7] Group 2 - NOA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, suggesting a strong potential for a turnaround [8]

Core Viewpoint - CVS Health has experienced significant selling pressure, with a 7.7% decline over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, supported by analyst expectations of better-than-previously predicted earnings [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that helps identify whether a stock is oversold, with readings below 30 indicating oversold conditions [2]. - CVS has an RSI reading of 29.64, suggesting that the heavy selling may be exhausting itself, indicating a potential bounce back towards equilibrium in supply and demand [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts to raise earnings estimates for CVS, with a 0.3% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [7]. - CVS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further indicating a potential turnaround [8].

Core Viewpoint - Steris (STE) has experienced significant selling pressure, declining 6% over the past four weeks, but is now positioned for a potential trend reversal as it is in oversold territory, with analysts expecting better earnings than previously predicted [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2]. - STE's current RSI reading is 27.46, suggesting that the heavy selling pressure may be exhausting itself, indicating a potential trend reversal [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for STE have increased by 0.1% over the last 30 days, which usually correlates with price appreciation in the near term [7]. - STE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8].

Core Viewpoint - Tandem Diabetes Care, Inc. (TNDM) has experienced a significant decline of 27% over the past four weeks, but it is now positioned for a potential trend reversal as it enters oversold territory, with analysts predicting better earnings than previously expected [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2] - TNDM's current RSI reading is 19.31, suggesting that the heavy selling pressure may be exhausting, indicating a potential bounce back towards equilibrium [5] Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that TNDM's earnings estimates for the current year have increased by 0.6% over the last 30 days, which often correlates with price appreciation [7] - TNDM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the stock's potential for a turnaround [8]

Group 1 - Abbott (ABT) has experienced a 9% decline over the past four weeks, but it is now in oversold territory, indicating a potential trend reversal [1] - The Relative Strength Index (RSI) for ABT is currently at 21.37, suggesting that the heavy selling pressure may be exhausting itself [5] - There is strong consensus among Wall Street analysts that ABT will report better earnings than previously predicted, with a 0% increase in the consensus EPS estimate over the last 30 days [7] Group 2 - ABT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8]

Core Viewpoint - New Gold (NGD) has experienced significant selling pressure, resulting in a 10% decline over the past four weeks, but analysts anticipate better earnings than previously expected, indicating potential for recovery [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) for NGD is currently at 28.3, indicating that the stock is in oversold territory, which may suggest a reversal in trend soon [5] - RSI is a momentum oscillator that helps identify whether a stock is overbought or oversold, with readings below 30 typically indicating oversold conditions [2][3] Group 2: Fundamental Indicators - There has been a strong consensus among sell-side analysts to raise earnings estimates for NGD, leading to a 20.5% increase in the consensus EPS estimate over the last 30 days, which often correlates with price appreciation [7] - NGD holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8]

Core Viewpoint - Concentra Group (CON) has experienced significant selling pressure, resulting in a 5.8% decline over the past four weeks, but analysts anticipate better earnings than previously predicted, indicating potential for recovery [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is utilized to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2]. - CON's current RSI reading is 28.87, suggesting that the heavy selling may be exhausting itself and a trend reversal could be imminent [5]. - RSI serves as a tool to identify potential price reversals, allowing investors to seek entry points for anticipated rebounds [3]. Group 2: Fundamental Analysis - Analysts have raised earnings estimates for CON, with a consensus EPS estimate increase of 0% over the last 30 days, which typically correlates with price appreciation [7]. - CON holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8].

Core Viewpoint - Alvotech (ALVO) is experiencing significant selling pressure, with a 6.6% decline over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, supported by positive earnings expectations from Wall Street analysts [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that helps identify whether a stock is oversold, with readings below 30 indicating oversold conditions [2]. - ALVO's current RSI reading of 28.6 suggests that the heavy selling may be exhausting, indicating a potential bounce back towards equilibrium in supply and demand [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts that earnings estimates for ALVO have increased by 6.3% over the last 30 days, which typically correlates with price appreciation in the near term [7]. - ALVO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further indicating a potential turnaround [8].